Nektar Therapeutics vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Nektar Therapeutics (NKTR)

Q3 202614 Aug – 7 Oct 2026

▼2▲1

Nektar's Lilly lawsuit ends with a $115M win, far below its $1B ask

Q2 loss narrower than expected, but revenue missed Nektar's second-quarter loss of $1.23 per share was far smaller than the $2.06 loss analysts expected, which supports the stock. But revenue of $10.1 million missed estimates and fell 9.8% from a year ago, so the beat came from cost control, not growth.
It is the period's first hard financial update and sets the baseline for how investors judge the company.
Cash burn stays heavy as Phase 3 trials run for years Nektar lost $40.6 million in the quarter and operating losses widened, while revenue is only non-cash royalties. Its $1.02 billion cash pile funds trials into 2028, but top-line results are not expected until mid-2028, so investors must wait years with no product sales.
It explains the core risk weighing on the stock: long, expensive trials with no near-term revenue.
Jury note in Lilly trial briefly wiped out $200M in value While the jury deliberated, a question about whether to award no damages or just $1 spooked investors, and the stock fell 11%. More than $200 million of market value vanished and never came back, showing how much the lawsuit's uncertainty was hurting the share price.
It captures the market's fear during the trial, the main event driving NKTR this period.
Lilly verdict won, but $115M is far short of the $1B sought Nektar won its contract case against Eli Lilly, with $90 million in damages plus interest totaling about $115 million, roughly 5% of its market value. That removes a legal cloud, but Nektar had sought up to $1 billion, and Lilly could still appeal.
It is the period's decisive event: a legal win that clears uncertainty but delivers far less money than hoped.

September 202614 Aug – 7 Oct 2026

▼2▲1

Nektar's Lilly lawsuit ends with a $115M win, far below its $1B ask

Q2 loss narrower than expected, but revenue missed Nektar's second-quarter loss of $1.23 per share was far smaller than the $2.06 loss analysts expected, which supports the stock. But revenue of $10.1 million missed estimates and fell 9.8% from a year ago, so the beat came from cost control, not growth.
It is the period's first hard financial update and sets the baseline for how investors judge the company.
Cash burn stays heavy as Phase 3 trials run for years Nektar lost $40.6 million in the quarter and operating losses widened, while revenue is only non-cash royalties. Its $1.02 billion cash pile funds trials into 2028, but top-line results are not expected until mid-2028, so investors must wait years with no product sales.
It explains the core risk weighing on the stock: long, expensive trials with no near-term revenue.
Jury note in Lilly trial briefly wiped out $200M in value While the jury deliberated, a question about whether to award no damages or just $1 spooked investors, and the stock fell 11%. More than $200 million of market value vanished and never came back, showing how much the lawsuit's uncertainty was hurting the share price.
It captures the market's fear during the trial, the main event driving NKTR this period.
Lilly verdict won, but $115M is far short of the $1B sought Nektar won its contract case against Eli Lilly, with $90 million in damages plus interest totaling about $115 million, roughly 5% of its market value. That removes a legal cloud, but Nektar had sought up to $1 billion, and Lilly could still appeal.
It is the period's decisive event: a legal win that clears uncertainty but delivers far less money than hoped.

Latest14 Aug – 7 Oct 2026

▼2▲1

Nektar's Lilly lawsuit ends with a $115M win, far below its $1B ask

Q2 loss narrower than expected, but revenue missed Nektar's second-quarter loss of $1.23 per share was far smaller than the $2.06 loss analysts expected, which supports the stock. But revenue of $10.1 million missed estimates and fell 9.8% from a year ago, so the beat came from cost control, not growth.
It is the period's first hard financial update and sets the baseline for how investors judge the company.
Cash burn stays heavy as Phase 3 trials run for years Nektar lost $40.6 million in the quarter and operating losses widened, while revenue is only non-cash royalties. Its $1.02 billion cash pile funds trials into 2028, but top-line results are not expected until mid-2028, so investors must wait years with no product sales.
It explains the core risk weighing on the stock: long, expensive trials with no near-term revenue.
Jury note in Lilly trial briefly wiped out $200M in value While the jury deliberated, a question about whether to award no damages or just $1 spooked investors, and the stock fell 11%. More than $200 million of market value vanished and never came back, showing how much the lawsuit's uncertainty was hurting the share price.
It captures the market's fear during the trial, the main event driving NKTR this period.
Lilly verdict won, but $115M is far short of the $1B sought Nektar won its contract case against Eli Lilly, with $90 million in damages plus interest totaling about $115 million, roughly 5% of its market value. That removes a legal cloud, but Nektar had sought up to $1 billion, and Lilly could still appeal.
It is the period's decisive event: a legal win that clears uncertainty but delivers far less money than hoped.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.